Literature DB >> 786677

Effect of nifedipine on exercise tolerance in patients with angina pectoris.

J H Atterhög, L G Ekelund, A L Melin.   

Abstract

To test if nifedipine, 10 mg sublingually, could increase exercise tolerance, ten patients with angina pectoris each performed two types of bicycle exercise test, one with a stepwise increase in load and the other with a continuously increasing load. The drug was given in a double-blind cross-over trial. Nifedipine raised the heart rate and diminished the systemic blood pressure at rest, on standing and during exercise at comparable loads. Work time was prolonged and higher work loads were achieved. The total work performed rose by 50 per cent in one of the tests and by 23 per cent in the other, about 50 minutes after taking the drug. The mechanism of the greater work capacity in angina pectoris after nifedipine was assumed to be diminished heart work due to a fall in systemic vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 786677     DOI: 10.1007/bf00561561

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  CIRCULATORY STUDIES ON HEALTHY OLD MEN. WITH SPECIAL REFERENCE TO THE LIMITATION OF THE MAXIMAL PHYSICAL WORKING CAPACITY.

Authors:  T STRANDELL
Journal:  Acta Med Scand Suppl       Date:  1964

2.  Hemodynamic and therapeutic effect of BAY a 1040 on the patients with ischemic heart disease.

Authors:  S Hayase; S Hirakawa; S Hosokawa; N Mori; S Kanyama
Journal:  Arzneimittelforschung       Date:  1972-02

3.  [BAY a 1040--a highly potent Ca ++ -antagonistic inhibitor of electro-mechanical coupling processes in mammalian myocardium].

Authors:  A Fleckenstein; H Tritthart; H J Döring; K Y Byon
Journal:  Arzneimittelforschung       Date:  1972-01

4.  [Effect of Nifedipine (BAY a 1040) on work electrocardiogram of angina pectoris patients].

Authors:  A Loos; M Kaltenbach
Journal:  Arzneimittelforschung       Date:  1972-02

5.  Cardiohemodynamic effects of BAY a 1040 in the dog.

Authors:  K Hashimoto; N Taira; S Chiba; K Hashimoto; M Endo
Journal:  Arzneimittelforschung       Date:  1972-01

6.  [The effect of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid methyl ester on myocardial metabolism, hemodynamics, blood gases and general metabolism of man].

Authors:  K Kochsiek; J Neubaur
Journal:  Arzneimittelforschung       Date:  1972-02

7.  [The indicative value of central hemodynamic changes following the administration of an o-nitrophenyl-dihydropyridine derivative].

Authors:  K W Schneider; R Jesse
Journal:  Arzneimittelforschung       Date:  1972-02

8.  Perceived exertion as an indicator of somatic stress.

Authors:  G Borg
Journal:  Scand J Rehabil Med       Date:  1970

9.  [Pharmacology of 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040)].

Authors:  W Vater; G Kroneberg; F Hoffmeister; H Saller; K Meng; A Oberdorf; W Puls; K Schlossmann; K Stoepel
Journal:  Arzneimittelforschung       Date:  1972-01

10.  [Electromechanical uncoupling of vascular smooth muscle as the basic principle of coronary dilatation by 4-(2'-nitrophenyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (BAY a 1040, Nifedipine). 1. The significance of Ca ++ ions for the bioelectrical and mechanical activity of smooth muscle].

Authors:  G Grün; A Fleckenstein
Journal:  Arzneimittelforschung       Date:  1972-02
View more
  11 in total

1.  Effects of nifedipine on cardiac function in patients with coronary artery disease evaluated with ambulatory radionuclide monitoring.

Authors:  H Kambara; I H Mohiuddin; N Tamaki; T Fudo; M Hayashi; R Nohara; J Konishi; C Kawai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  A haemodynamic and radionuclide assessment of diltiazem in coronary heart disease.

Authors:  B Silke; S K Sharma; S P Verma; K A Midtbo; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

3.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

4.  Changes in haemodynamics and left ventricular function during intravenous nifedipine infusion with and without additional propranolol in patients with coronary artery disease. A randomized, placebo controlled trial.

Authors:  M Mauser; W Voelker; D Roser; K R Karsch; L Seipel
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Authors:  B Silke; S P Verma; A V Zezulka; S Sharma; G Reynolds; N C Jackson; S Guy; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

6.  Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.

Authors:  B Silke; S P Verma; S Guy
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

Review 7.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

8.  Haemodynamic dose-response effects of intravenous nisoldipine in coronary artery disease.

Authors:  B Silke; M A Frais; P Muller; S P Verma; G Reynolds; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

9.  Pharmacokinetic, haemodynamic and radionuclide studies with nicardipine in coronary artery disease.

Authors:  B Silke; D J Graham; S P Verma; G Reynolds; M A Frais; J R Finlayson; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  The combination of nifedipine and propranolol in the management of patients with angina pectoris.

Authors:  A C Tweddel; J M Beattie; R G Murray; I Hutton
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.